ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00874770
Recruitment Status : Completed
First Posted : April 3, 2009
Results First Posted : October 23, 2015
Last Update Posted : October 23, 2015
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Study Description
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.

Condition or disease Intervention/treatment Phase
Hepatitis C Infection Drug: Daclatasvir Drug: Placebo Drug: Peginterferon alpha-2a Drug: ribavirin Phase 2

Study Design
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1
Study Start Date : June 2009
Actual Primary Completion Date : November 2009
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)
Active Comparator
 Drug: Daclatasvir
Tablets, oral, 3 mg, Daily, 48 weeks
Drug: Peginterferon alpha-2a
Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
Other Name: Pegasys
Drug: ribavirin
Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
Other Name: Copegus
Experimental: Daclatasvir, Peginterferon alpha-2a, ribavirin (B)
Active Comparator
 Drug: Daclatasvir
Tablets, oral, 10 mg, Daily, 48 weeks
Drug: Peginterferon alpha-2a
Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
Other Name: Pegasys
Drug: ribavirin
Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
Other Name: Copegus
Experimental: Daclatasvir, Peginterferon alpha-2a, ribavirin (C)
Active Comparator
 Drug: Daclatasvir
Tablets, oral, 60 mg, Daily, 48 weeks
Drug: Peginterferon alpha-2a
Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
Other Name: Pegasys
Drug: ribavirin
Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
Other Name: Copegus
Active Comparator: Placebo, Peginterferon alpha-2a, ribavirin (D) Drug: Placebo
Tablet, oral, 0 mg, Daily 48 weeks
Drug: Peginterferon alpha-2a
Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
Other Name: Pegasys
Drug: ribavirin
Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
Other Name: Copegus


Outcome Measures
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of Participants With Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12 [ Time Frame: A Weeks 4 and 12 ]
    eRVR was defined as undetectable hepatitis C virus RNA less than the lower limit of detection (10 IU/mL) at Weeks 4 and 12.


Secondary Outcome Measures :
  1. Percentage of Participants With Rapid Virologic Response (RVR) at Week 4 [ Time Frame: At Week 4 ]
    RVR was defined as undetectable hepatitis C virus (HCV) RNA ie, HCV RNA less than the lower limit of detection (10 IU/mL) at Week 4.

  2. Percentage of Participants With Early Virologic Response (EVR) at Week 12 [ Time Frame: At Week 12 ]
    EVR was defined as a ≥2 log10 decrease in hepatitis C virus (HCV) RNA from baseline at Week 12 , or HCV RNA <10 IU/mL for participants with baseline HCV RNA <1000 IU/mL.

  3. Percentage of Participants With a Complete Early Virologic Response (cEVR) at Week 12 [ Time Frame: At Week 12 ]
    cEVR was defined as hepatitis C virus RNA <10 IU/mL at Week 12


Other Outcome Measures:
  1. Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Treatment-related AEs and Who Died in Treatment Phase [ Time Frame: SAE: From Day 1 up to 30 days after last dose of study drug, AE: From Day 1 to 7 days after last dose of study drug ]
    An AE was defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a patient or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Treatment-related AE was defined as an AE that had certain, probable, possible, or unknown relationship to study drug.

  2. Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Treatment-related AEs and Who Died in Follow-up Period [ Time Frame: From Day 31 up to Week 24 of post treatment follow-up ]
    An AE was defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a patient or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Treatment-related AE was defined as an AE that had certain, probable, possible, or unknown relationship to study drug.

  3. Number of Participants With Grade 3 to 4 Abnormalities on Laboratory Test Results [ Time Frame: From screening up to Week 12 (treatment period) ]
    Clinically significant change in marked laboratory abnormalities (Grade 3 to 4 ) included: Alanine aminotransferase (ALT)- Grade 3 as >5.0 to 10.0* Upper Limit of Normal (ULN), Grade 4 as >10.0*ULN; Aspartate aminotransferase (AST)- Grade 3 as >5.0 to 10.0*ULN, Grade 4 as >10.0*ULN; Hemoglobin- Grade 3 as 7.0 to 8.9 g/dL, Grade 4 as <7.0 g/dL; Neutrophils- Grade 3 as 0.5 to 0.749*10^9/L, Grade 4 as <0.5*10^9/L; Lymphocytes- Grade 3 as 0.35 to 0.499*10^9/L, Grade 4 as <0.35*10^9/L; Total Bilirubin- Grade 3 as 2.6-5.0*ULN, Grade 4 as >5.0*ULN; Platelets- Grade 3 as 25000 to 49999*10^9/L, Grade 4 as <25000 10^9/L and white blood cells (WBC) - Grade 3 as 1000 to 1499*10^9/L, Grade 4 as <1000*10^9/L.


Eligibility Criteria
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Patients chronically infected with hepatitis C virus (HCV) genotype 1
  • HCV RNA viral load of ≥10*5* IU/mL (100,000 IU/mL) at screening
  • Treatment naive

Key Exclusion Criteria:

  • Women of child-bearing potential
  • Cirrhosis
  • Coinfection with HIV or hepatitis B virus
Contacts and Locations
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00874770


Locations
United States, Alabama
Alabama Liver & Digestive Specialists (Alds)
Montgomery, Alabama, United States, 36116
United States, Colorado
University Of Colorado Denver & Hospital
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale University School Of Medicine
New Haven, Connecticut, United States, 06520
United States, Maryland
Mercy Medical Center
Baltimore, Maryland, United States, 21202
United States, Massachusetts
Llc Dba The Research Institute
Springfield, Massachusetts, United States, 01107
United States, New York
Veterans Affairs Medical Center
Bronx, New York, United States, 10468
United States, North Carolina
Carolinas Center For Liver Disease
Statesville, North Carolina, United States, 28677
United States, Oklahoma
Options Health Research, Llc
Tulsa, Oklahoma, United States, 74104
Healthcare Research Consultants
Tulsa, Oklahoma, United States, 74135
United States, Texas
North Texas Research Institute
Arlington, Texas, United States, 76012
United States, Virginia
Metropolitan Research
Fairfax, Virginia, United States, 22031
France
Local Institution
Creteil, France, 94010
Local Institution
Paris Cedex 14, France, 75679
Local Institution
Vandoeuvre Les Nancy, France, 54511
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
More Information
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
Investigator Inquiry form  This link exits the ClinicalTrials.gov site
For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm  This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00874770     History of Changes
Other Study ID Numbers: AI444-014
EUDRACT# 2009-010149-29
First Posted: April 3, 2009    Key Record Dates
Results First Posted: October 23, 2015
Last Update Posted: October 23, 2015
Last Verified: September 2015

Keywords provided by Bristol-Myers Squibb:
Antivirals

Additional relevant MeSH terms:
Hepatitis
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Ribavirin
 Peginterferon alfa-2a
Interferon-alpha
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs